iev407
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Advanced HR+/HER2- Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM MedSIR | Phase 2 | B |
Loperamide MedSIR | Phase 2 | B |
Atropine MedSIR | Phase 2 | CCC |
FULVESTRANT Novartis Pharmaceuticals | Phase 1/2 | CCC |
Letrozole Novartis Pharmaceuticals | Phase 1/2 | CCC |
View all 11 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →